{"id":390641,"date":"2018-06-20T00:00:00","date_gmt":"2018-06-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0020-2018-biopharma-bipolar-depression-unmet-need-us-eu-2018\/"},"modified":"2026-04-21T11:26:36","modified_gmt":"2026-04-21T11:26:36","slug":"unnecg0020-2018-biopharma-bipolar-depression-unmet-need-us-eu-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0020-2018-biopharma-bipolar-depression-unmet-need-us-eu-2018\/","title":{"rendered":"Bipolar Depression | Unmet Need | US\/EU | 2018"},"content":{"rendered":"<p>Bipolar disorder is a spectrum disorder that encompasses two symptom domains: mania and depression. The symptoms of bipolar depression can include fatigue, insomnia, suicidal ideation, and feelings of worthlessness. Presently, there are a handful of therapies approved to treat bipolar depression, but none can sufficiently address this symptom domain, in particular the acute treatment of patients\u2019 depressive symptoms. Thus, treatments with a rapid onset of therapeutic action are needed. Understanding the drivers of clinical decision-marking in the treatment of bipolar depression will help drug developers focus on agents that fulfill the indication\u2019s treatment needs and help marketers determine how to leverage their products\u2019 attributes.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are surveyed psychiatrists\u2019 opinion of the relative performances of bipolar depression therapies, including aripiprazole (Otsuka Pharmaceutical\u2019s Abilify, generics) and lurasidone (Sunovion\u2019s Latuda), on key efficacy, safety\/tolerability, and convenience of administration attributes?<\/li>\n<li>Based on the responses of surveyed physicians, what level of unmet need exists on key drug performance attributes?<\/li>\n<li>What attributes drive decision-making in the treatment of bipolar depression, which have limited impact, and which are hidden opportunities? How do off-label treatments perform on these attributes?<\/li>\n<li>Based on a conjoint analysis and TPP simulation, what trade-offs between efficacy, safety, convenience of administration, and price are psychiatrists willing to make for a hypothetical new drug to treat bipolar depression?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Unmet Need: Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered: <\/strong>United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. psychiatrists and 31 psychiatrists in Europe.<\/p>\n<p><strong>Key companies:<\/strong> AstraZeneca, Lundbeck A\/S, Otsuka Pharmaceuticals, Sunovion<\/p>\n<p><strong>Key drugs: <\/strong>Aripiprazole (Abilify, generics), lamotrigine (Lamictal, generics), lithium, Latuda, and sertraline (Zoloft, generics)<\/p>\n<p><strong>Key metrics included:<\/strong><\/p>\n<ul>\n<li>Stated versus derived analysis of U.S. and European physician prescribing behavior.<\/li>\n<li>Conjoint analysis with U.S. and European physicians, includes market simulator.<\/li>\n<li>Assessment of current drug performance against treatment drivers and goals.<\/li>\n<li>Physician perceptions of unmet need in subpopulation(s) covered and related diseases\/subpopulations.<\/li>\n<li>Analysis of remaining drug development opportunities.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390641","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390641\/revisions"}],"predecessor-version":[{"id":393765,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390641\/revisions\/393765"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}